Mining the Plasma Cell Transcriptome for Novel Cell Surface Proteins.

Area of Science:

• Immunology
• Cell Biology
• Oncology

Background:

• Antibody Secreting Cells (ASCs) are crucial for humoral immunity but implicated in autoimmune diseases and Multiple Myeloma (MM).
• Current treatments for MM and autoimmune diseases lack ASC-specific therapies, creating a need for targeted approaches.
• Surface molecules on target cells are ideal for monoclonal antibody-based therapies.

Purpose of the Study:

• To identify and validate novel surface protein targets on ASCs and MM cells for therapeutic intervention.
• To investigate the functional role of identified surface proteins in B-lymphocyte development and ASC function.

Main Methods:

• Analysis of a previously defined ASC gene signature to identify potential surface targets.
• Generation of mouse strains with loss-of-function mutations in Plpp5, Clptm1l, and Itm2c.
• Phenotypic analysis of mutant mice to assess B-lymphocyte development, ASC function, and potential disease phenotypes.

Main Results:

• Plpp5, Clptm1l, and Itm2c were identified as highly and selectively expressed on mouse and human ASCs and MM cells.
• Mice lacking Plpp5, Clptm1l, or Itm2c showed normal B-lymphocyte development, maturation, differentiation, and antibody production.
• Adult mice deficient in these proteins exhibited no apparent disease phenotypes.

Conclusions:

• Plpp5, Clptm1l, and Itm2c are dispensable for normal humoral immunity.
• These proteins represent promising, highly selective therapeutic targets for Multiple Myeloma.
• Targeting these ASC-specific molecules may offer a therapeutic strategy with minimal on-target adverse effects.